Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:antineoplastic_agent gptkb:nitrosourea |
| gptkbp:ATCCode |
gptkb:L01AD02
|
| gptkbp:CASNumber |
gptkb:13010-47-4
|
| gptkbp:color |
yellow
|
| gptkbp:discoveredIn |
1970s
|
| gptkbp:eliminationHalfLife |
16-48 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
capsule
|
| gptkbp:hasMolecularFormula |
C9H16ClN3O2
|
| gptkbp:KEGGID |
D00441
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
gptkb:antineoplastic_agent
|
| gptkbp:meltingPoint |
89-90°C
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
>50%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1427
gptkb:DB01206 36136 39549 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting pulmonary fibrosis myelosuppression |
| gptkbp:synonym |
gptkb:CCNU
|
| gptkbp:UNII |
7A5I2794F1
|
| gptkbp:usedFor |
treatment of Hodgkin's lymphoma
treatment of brain tumors |
| gptkbp:bfsParent |
gptkb:multidrug_resistance-associated_protein_1
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
lomustine
|